Perspective Therapeutics Inc Stock Price, News & Analysis

Perspective Therapeutics (NYSE AMERICAN: CATX) has begun shipping investigational products from its new radiopharmaceutical manufacturing facility in Somerset, New Jersey. This state-of-the-art facility is now operational, supporting VMT-α-NET clinical studies alongside the existing Coralville, Iowa facility. With three cGMP-compliant manufacturing suites, it's expected to meet future clinical trial and commercial demands in the Northeastern U.S.

The Somerset facility, acquired from Lantheus Holdings in March 2024, previously produced FDA-approved Azedra for rare adrenal gland tumors. This milestone comes just seven months after acquisition, accelerating Perspective's efforts in delivering investigational products and potential new radiopharmaceutical therapies. The company aims to replicate this approach, adding strategic sites to enhance its network supporting key treatment hubs across the U.S.

Perspective Therapeutics (NYSE AMERICAN: CATX) presented initial results from its Phase 1/2a study of [212Pb]VMT01, a MC1R-targeted radiopharmaceutical therapy for melanoma, at the 21st International Congress of the Society for Melanoma Research. Key findings include:

1. Safety: No dose-limiting toxicities observed at 3.0 and 5.0 mCi doses.

2. Efficacy: Prolonged progression-free survival and tumor response in heavily pretreated patients at the 3.0 mCi dose.

3. The trial is progressing with a lower 1.5 mCi dose to optimize immunostimulatory activities, both as monotherapy and in combination with nivolumab.

4. The Safety Monitoring Committee recommended exploring the 1.5 mCi dose level as a single agent and in combination with nivolumab.

Perspective Therapeutics (NYSE AMERICAN: CATX), a radiopharmaceutical company, announced that initial results from its Phase 1/2a study of [212Pb]VMT01 have been selected for a poster presentation at the 21st International Congress of the Society for Melanoma Research (SMR). The event will be held on October 10-13, 2024, in New Orleans, Louisiana.

The study, titled “First in Human Peptide Receptor Radionuclide Therapy (PRRT) for Metastatic Melanoma (MM),” marks the company's first scientific presentation of clinical data from a company-sponsored study. CEO Thijs Spoor highlighted the ongoing exploration of the optimal dose of [212Pb]VMT01 in metastatic melanoma, both as a single agent and in combination with nivolumab.

Perspective will host a conference call on October 11, 2024, at 9am ET to review the data presented at SMR. Details will be available on the Events page of the company's website.

Perspective Therapeutics (NYSE AMERICAN: CATX), a radiopharmaceutical company, announced its participation in two upcoming events: the Oppenheimer Targeted Radiopharmaceutical Therapies in Oncology Summit on October 8, 2024, in New York, NY, and the JonesResearch Virtual Radiopharma Day on October 29, 2024.

At the Oppenheimer Summit, Perspective's senior management will participate in two panel discussions: 'The Next Wave of TRTs – Targets, Targeting Technologies and Isotopes' from 9:30 a.m. to 10:30 a.m. ET, and 'Supply Chain Challenges and Controversies: Ac225 Availability, Pb212 Logistics, The Last Mile' from 10:50 a.m. to 11:35 a.m. ET. They will also give a company presentation at 1:30 p.m. ET.

The JonesResearch event will feature a panel format. Webcasts for both events will be accessible live and archived for 90 days on the Perspective website's Investors page.

Perspective Therapeutics (NYSE AMERICAN: CATX) will present updated preclinical data on PSV359 at the 37th Annual Congress of the European Association of Nuclear Medicine (EANM) in Hamburg, Germany, from October 19-23, 2024. The company will showcase several presentations, including:

1. Preclinical evaluation and first-in-human imaging of [203/212Pb]Pb-PSV359, targeting fibroblast activation protein-alpha (FAP).

2. Impact of molar activity on [203Pb]Pb-VMT-α-NET biodistribution in neuroendocrine tumor xenografts.

3. Interim results of 212Pb-VMT-α-NET Targeted Alpha Therapy in metastatic gastro-entero-pancreatic neuroendocrine tumors.

4. Image-guided evaluation of 212Pb-VMT-α-NET in metastatic neuroendocrine tumors.

The presentations will include updated analyses from investigator-led clinical research and preclinical studies, focusing on novel radiopharmaceutical treatments for various cancers.

Perspective Therapeutics (NYSE AMERICAN: CATX) presented updates on its alpha-particle radiopharmaceuticals at the World Molecular Imaging Congress 2024 in Québec, Canada. The company showcased two key presentations:

1. Preclinical evaluation of [203/212Pb]Pb-PSV-359 for imaging and alpha-particle therapy of cancers expressing fibroblast activation protein (FAP). The study demonstrated superior FAP binding affinity, strong tumor uptake, and anti-tumor effects in xenograft models.

2. Customizing chelators for targeted radionuclide therapy using computational modeling. The research highlighted the importance of matching chelators to specific radionuclides for optimal stability and targeted delivery in targeted radionuclide therapy (TRT).

CEO Thijs Spoor expressed satisfaction with the additional data supporting the development of their alpha-particle therapies, emphasizing the need for customized chelators and the favorable safety and efficacy profiles of their FAP-targeting candidate, PSV-359.

Perspective Therapeutics (NYSE AMERICAN: CATX) has received Fast Track Designation from the FDA for its 212Pb VMT01 product, targeting the diagnosis and treatment of unresectable or metastatic melanoma with MC1R tumor expression. This designation expedites development and review processes, offering more frequent FDA interactions and eligibility for accelerated approval, priority review, and rolling review.

The company has completed the observation period for dose-limiting toxicity in seven patients in Cohort 2 of its Phase 1/2a study. Perspective plans to share safety observations with the Safety Monitoring Committee and in a scientific forum later this year. Additionally, they intend to open a VMT01/anti-PD-1 combination cohort, pending institutional review board approval.

Perspective Therapeutics (NYSE AMERICAN: CATX), a radiopharmaceutical company focusing on advanced cancer treatments, has announced its participation in three upcoming investor conferences in September 2024. The company's senior leadership will be available for one-on-one meetings with investors at these events:

1. Morgan Stanley 22nd Annual Global Healthcare Conference on September 6 in New York, featuring a fireside chat.

2. 2024 Cantor Global Healthcare Conference on September 17 in New York, also with a fireside chat format.

3. 10th Annual World Medical Innovation Forum on September 24 in Boston, where Perspective will participate in a panel discussion on 'The Biologic Revolution in Radiotherapies'.

Webcasts of these events will be accessible live and archived for 90 days on the company's investor webpage.

Perspective Therapeutics (NYSE AMERICAN: CATX) reported fiscal Q2 2024 results and business highlights. Key points include:

• Completed enrollment of initial Cohort 2 patients in VMT-α-NET and VMT01 clinical trials
• On track to advance multiple pre-IND assets to clinic in 12-18 months
• Progressing on manufacturing infrastructure build-out
• $293 million cash balance expected to fund operations into mid-2026
• Q2 revenue: $0.5 million; R&D expenses: $9.3 million; G&A expenses: $5.5 million
• Net loss: $11.7 million or $0.18 per share

The company is advancing its radiopharmaceutical pipeline and manufacturing capabilities while maintaining a strong cash position to fund ongoing clinical and pre-clinical programs.